A Prospective Study Investigating the Effects of a Novel Weight Management Program

Pharmanex

Status: Completed

Conditions: Overweight

Treatments: Dietary Supplement: Placebo and Low Fat Eating Plan; Dietary Supplement: Dietary Supplements and TR90 Eating Plan

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01875354

13-PHX-01-NU-02

Details and patient eligibility

About

The purpose of this study is to assess the safety and efficacy of a weight management program composed of dietary supplements and a reduced calorie eating program.

Enrollment: 141 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Male or female 18-65 years of age at the time of informed consent
2. The ability to read, speak and understand the English language in order to complete the required paper informed consent, assessments and diary
3. Access to email and to a digital camera or camera phone
4. Willing and able to provide written informed consent
5. Willing and able to comply with the study restrictions, procedures and assessments and attend regularly scheduled clinic visits
6. Willing and able to accommodate being contacted by the study staff for telephone call visits, follow-up contacts, and study visit reminders
7. BMI is equal to or greater than 25 and less than or equal to 40 kg/m2
8. Use of effective method of contraception by females of childbearing potential 30-days before the screening visit and agree to continue to practice that acceptable method of contraception for the duration of her participation in the study
9. A resting normotensive blood pressure, as defined as a systolic blood pressure between 150-90 mmHg and a diastolic blood pressure of between 95-50 mmHg, at screening visit 1(A)
10. Willing to fast for at least 8 hours prior to the study procedures being performed that require fasting measurements
11. Willing and able to follow eating program and able to consume the study supplied Supplements, Placebos and shakes (which include whey and/or egg protein) on a daily basis. Subjects that are lactose intolerant will be considered ineligible
12. Only one member per household eligible to participate in the study

Exclusion criteria

1. A subject that has any Axis I Psychiatric disorders according to the DSM-IV criteria that would prevent the subject from being able to comply with study requirements and/or taking anti-psychotic medication
2. Diagnosed with insomnia and is chronically using prescribed or OTC insomnia medications
3. A self-reported chronic condition that may affect subject safety
4. An HbA1c of greater than or equal to 7.0%
5. Renal insufficiency as defined by a laboratory Glomerular Filtration Rate of less than 50 mL/min/1.73 m2
6. Chronically using glucocorticoid steroids
7. Currently pregnant, planning to become pregnant during the course of the study or is breastfeeding
8. Use of antihypertensive medication(s) for less than 90 days prior to screening
9. Diagnosed with any thyroid disorder or has a clinically significant out of range laboratory value (i.e. TSH, T3 Free, and/or T4 Free) value measured at screening
10. Known allergy or intolerance to any of the ingredients contained in the Novel Supplements, placebos or shakes (cow milk proteins)
11. Planned surgical procedure during the 365 day course of the study
12. Currently participating in another clinical research study or have done so within 30 days prior to the screening visit
13. Diagnosis of milk or egg intolerance
14. Participating in another weight loss program or using another weight loss product. Subjects may enroll if they are willing to stop the weight loss program they are currently on and/or washout of the product they are using. The appropriate washout will be reviewed with the investigator or medically qualified designee on a case by case basis
15. Fasting LDL-C greater than 190 mg/dL or triglycerides greater than 400 mg/dL.
16. Unwilling to discontinue consumption of green or black tea or green or black tea extracts beginning at the screening visit and after signing of the informed consent
17. Unwilling to discontinue use of over-the-counter and/or prescribed vitamin supplements except for: multivitamins, calcium, fish oil, vitamin C, vitamin D, vitamin E, zinc or iron
18. Plans to have plastic or reconstructive surgery or any other procedure that, in the opinion of the investigator, could influence body composition, at any time during the year long study
19. Unable to lay supine for at least 30 minutes
20. Cognitive impairment that would limit ability to understand or follow diet instructions and/or comply with the study protocol

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

141 participants in 2 patient groups, including a placebo group

Placebo and Low Fat Eating Plan

Placebo Comparator group

Description:

Placebo Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Placebo Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Placebo Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal) The placebo group will be instructed to consume every day, a low fat standard of care eating plan delivering approximately 1200-1500 Kcals.

Treatment:

Dietary Supplement: Placebo and Low Fat Eating Plan

Dietary Supplements and TR90 Eating Plan

Experimental group

Description:

Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal) Experimental group will be instructed to consume every day, dietary supplements and a moderate protein eating plan delivering approximately 1200-1500 Kcals.

Treatment:

Dietary Supplement: Dietary Supplements and TR90 Eating Plan